Novo CEO pressed by Senate to chop costs of obesity, diabetes drugs CEO Lars Fruergaard Jørgensen advised lawmakers the corporate would take into account new talks with insurers concerning the record rates of Wegovy and copyright should they pledge to keep the medicines on their formularies. This plan aligns with https://aya-healthcare-address94948.theisblog.com/30848907/not-known-facts-about-healthcare-news